ZILRYENZ Trademark

Trademark Overview

On Thursday, July 6, 2017, a trademark application was filed for ZILRYENZ with the United States Patent and Trademark Office. The USPTO has given the ZILRYENZ trademark a serial number of 87517344. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 1, 2022. This trademark is owned by Bristol-Myers Squibb Company. The ZILRYENZ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection - all of the foregoing excluding pharmaceutical preparations and substances for the treatment and/or management of sleep disorders, namely, narcolepsy; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants and pharmaceutical antibodies - all of the foregoing excluding pharmaceutical preparations and substances for the treatment and/or management of sleep disorders, namely, narcolepsy
zilryenz

General Information

Serial Number87517344
Word MarkZILRYENZ
Filing DateThursday, July 6, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 1, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 1, 2018

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection - all of the foregoing excluding pharmaceutical preparations and substances for the treatment and/or management of sleep disorders, namely, narcolepsy; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants and pharmaceutical antibodies - all of the foregoing excluding pharmaceutical preparations and substances for the treatment and/or management of sleep disorders, namely, narcolepsy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 13, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10016
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10154

Trademark Events

Event DateEvent Description
Monday, August 1, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 1, 2022ABANDONMENT - NO USE STATEMENT FILED
Friday, December 17, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 16, 2021SOU EXTENSION 5 GRANTED
Wednesday, December 8, 2021SOU EXTENSION 5 FILED
Thursday, December 16, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, December 8, 2021TEAS EXTENSION RECEIVED
Saturday, June 19, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 17, 2021SOU EXTENSION 4 GRANTED
Thursday, June 17, 2021SOU EXTENSION 4 FILED
Thursday, June 17, 2021TEAS EXTENSION RECEIVED
Saturday, December 26, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 24, 2020SOU EXTENSION 3 GRANTED
Thursday, December 24, 2020SOU EXTENSION 3 FILED
Thursday, December 24, 2020TEAS EXTENSION RECEIVED
Thursday, June 25, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 23, 2020SOU EXTENSION 2 GRANTED
Tuesday, June 23, 2020SOU EXTENSION 2 FILED
Tuesday, June 23, 2020TEAS EXTENSION RECEIVED
Wednesday, December 25, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 23, 2019SOU EXTENSION 1 GRANTED
Monday, December 23, 2019SOU EXTENSION 1 FILED
Monday, December 23, 2019TEAS EXTENSION RECEIVED
Tuesday, June 25, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, November 8, 2018EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Wednesday, October 24, 2018CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Wednesday, October 24, 2018ASSIGNED TO PETITION STAFF
Monday, October 8, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, October 8, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, September 21, 2018TEAS POST PUBLICATION AMENDMENT RECEIVED
Thursday, May 31, 2018EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, May 1, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 1, 2018PUBLISHED FOR OPPOSITION
Wednesday, April 11, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, March 26, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, March 22, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 21, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 21, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 28, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 28, 2017NON-FINAL ACTION E-MAILED
Thursday, September 28, 2017NON-FINAL ACTION WRITTEN
Wednesday, September 27, 2017ASSIGNED TO EXAMINER
Thursday, July 13, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, July 10, 2017NEW APPLICATION ENTERED IN TRAM

Related Keywords

zilryenz diseases pharmaceutical disorders preparations namely treatment sleep excluding foregoing substances